Publications by authors named "F Aboubakar Nana"
Background: Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited.
Methods: This is an international multicenter retrospective study of patients with cancer and cardiac metastasis at baseline. Patients who had received ≥1 dose of ICI were included.
Although the incidence of systemic thromboembolism in valvular heart disease has been reported to be as high as 10% to 35%, embolization to the coronary arteries is uncommon. We present a case of a patient with acute myocardial infarction caused by coronary thromboemboli associated with combined valvular heart disease and atrial fibrillation. The thromboemboli were documented in the left descending artery.
View Article and Find Full Text PDFArticle Synopsis
- - Patients with paraneoplastic syndromes (PNS) are often excluded from clinical trials for immune checkpoint inhibitors (ICIs) due to potential safety risks, leading to a lack of real-world data on their efficacy and safety for these patients.
- - A study analyzed data from 109 PNS patients with solid tumors treated with ICIs between 2015 and 2022, finding that 29% of those with pre-existing PNS experienced exacerbations shortly after starting ICI therapy, and a significant portion required immunosuppressive treatment.
- - No significant differences in overall survival (OS) or time-to-next treatment (TTNT) were observed between patients with metastatic non-small cell lung cancer (mNSCLC) with P
Background: Restin is a member of the melanoma-associated antigen (MAGE) superfamily. Its expression has been reported to be up- or downregulated in cancer. Preclinical data suggest it is a tumor suppressor.
View Article and Find Full Text PDFIntroduction: Chemotherapy plus immunotherapy is the standard of care for patients with metastatic NSCLC. No study has evaluated the outcomes of second-line chemotherapy treatments after progression following first-line chemo-immunotherapy.
Method: This multicenter retrospective study evaluated the efficacy of second line (2L) chemotherapies after progression under first-line (1L) chemo-immunotherapy, measured by overall survival (2L-OS) and progression free survival (2L-PFS).